Chondrosarcoma News and Research

RSS

CHG may be the most effective irrigation solution for use during surgical treatment of bone tumors

The widely used disinfectant chlorhexidine gluconate (CHG) appears to be the most effective irrigation solution for use as part of the surgical treatment of bone tumors, suggests an experimental study in The Journal of Bone & Joint Surgery.

28 Oct 2022

NCCN publishes new informational resources on health and wellness for cancer survivors

Today, the National Comprehensive Cancer Network announced the publication of new, free informational resources on health and wellness for cancer survivors.

5 Jan 2021

Findings may open up new ways to treat dwarfism and other ER-stress-related conditions

Pseudoachondroplasia (PSACH) is a severe inherited dwarfing condition characterized by disproportionate short stature, joint laxity, pain, and early onset osteoarthritis.

12 Dec 2018

Chemical stimuli by small molecule can improve production of cartilage cells

Cell-based therapies could offer a way to treat cartilage injuries before the ultimate damage of osteoarthritis on articular cartilage.

11 May 2017

Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute.

7 Jun 2016

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

American Income Life donates $10,000 to Sarcoma Foundation of America

American Income Life Insurance Company, headquartered in Waco, TX, in partnership with State General Agents Tom Williams and David Zophin, donated $10,000 to the Sarcoma Foundation of America (South Florida Chapter) as part of the Company's Closer to the Heart program of charitable giving.

14 Sep 2015

Loyola study examines survival outcomes in patients with mesenchymal chondrosarcoma

Among the deadliest cancers is a rare malignancy called mesenchymal chondrosarcoma, which begins in cartilage around bones and typically strikes young adults.

13 May 2015

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

Absence of Shp-2 enzyme near cartilage cells can lead to multiple benign cartilage tumors in mice

Rhode Island Hospital researchers have found that the absence of the Shp-2 enzyme near specialized cartilage cells can lead to the development of multiple benign cartilage tumors in mice, a model that recapitulates the rare human tumor syndrome metachondromatosis.

20 Jul 2013

Infinity voluntarily stops saridegib Phase 2 trial for chondrosarcoma

Infinity Pharmaceuticals, Inc. today announced interim data from its Phase 2, double-blind, randomized, placebo-controlled study of saridegib (IPI-926) in patients with metastatic or locally advanced, inoperable chondrosarcoma. The primary endpoint of the Phase 2 study was progression-free survival.

18 Jun 2012

New data from Infinity saridegib and gemcitabine Phase 1b/2 combination trial on pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced updated data from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of saridegib in combination with the chemotherapy gemcitabine in patients with previously untreated, metastatic pancreatic cancer.

20 Jan 2012

Infinity third quarter total revenue increases marginally to $23.3 million

Infinity Pharmaceuticals, Inc. today highlighted its recent clinical and business progress and announced its third quarter 2011 financial results.

9 Nov 2011

Mount Sinai researchers identify protein signaling hyperactivity in human sarcoma cells

Researchers from Mount Sinai School of Medicine have discovered a protein signaling pathway that becomes hyperactivated in human sarcoma cells, suggesting that medications to inhibit this pathway may be effective in the treatment of human sarcomas. The research is published in the current issue of the journal Cancer Cell.

24 May 2011

First pelvic reconstruction surgery in cancer patient performed at Ohio State's Medical Center

In a rare and medically remarkable operation, a multi-disciplinary team of surgeons at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute removed the left leg, hip and pelvis of a cancer patient, and used the healthy, living bones from his amputated leg to completely rebuild the connection between his spine and remaining right pelvis to support a high-tech prosthetic leg.

6 May 2011

Worm protein controls key aspects of secretion of growth factors out of cells

Research in the worm is shedding light on a protein associated with a number of different human cancers, and may point to a highly targeted way to treat them.

22 Apr 2011

Patients with bone cancer can benefit from radical surgery

During a radical surgery to treat a rare bone cancer, surgeons at UC San Diego Health System and Moores Cancer Center removed 50 percent of a patient's pelvis. Instead of amputating the connected leg, the surgical team, comprised of orthopaedic, vascular and urologic experts, saved the entire limb. The patient was able to walk with assistance five weeks after surgery.

22 Mar 2011

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma. The trial is expected to enroll over 100 patients worldwide.

3 Mar 2011

John Theurer chief to present videos on new limb-sparing surgical techniques at AAOS conference

James C. Wittig, M.D., chief of the division of skin and sarcoma cancer at the John Theurer Cancer Center at Hackensack University Medical Center will present eleven different educational videos on innovative approaches to orthopedic oncology at the upcoming American Academy of Orthopaedic Surgeons Conference.

20 Feb 2011

VA begins distributing disability benefits to Vietnam Veterans exposed to Agent Orange

The Department of Veterans Affairs (VA) has begun distributing disability benefits to Vietnam Veterans who qualify for compensation under recently liberalized rules for Agent Orange exposure.

2 Nov 2010